Roche Achieves 44% Mortality Reduction with Divarasib in Phase III KRAS-Mutant Lung Cancer Trial

A 44% reduction in risk of death positions Roche's divarasib as a credible candidate for accelerated regulatory review, and the Phase III readout will now sharpen CMC scrutiny for KRAS G12C-targeted small molecules across both FDA and EMA dossiers. For regulatory affairs leads tracking oncology submissions, the data package assembled around this trial will set a visible benchmark for the class.

The trial evaluated divarasib in patients with advanced non-small cell lung cancer harboring the KRAS G12C mutation, a subtype historically resistant to targeted intervention. A 44% reduction in mortality risk is a clinically meaningful endpoint that typically supports a Priority Review designation under 21 CFR Part 312 and may qualify for Breakthrough Therapy consideration if not already designated. Roche has not publicly confirmed which expedited pathway it intends to pursue with FDA or EMA at this stage.

From a manufacturing readiness standpoint, KRAS-targeted small molecules present defined process chemistry challenges: synthetic route complexity, chiral center control, and polymorph stability each carry weight in the ICH Q11 development and manufacture section of a New Drug Application. QA directors overseeing tech transfer for oncology portfolios should anticipate heightened agency focus on process validation data and impurity profiling, particularly given the competitive regulatory attention this target has attracted since sotorasib's approval in 2021.

Supply chain leads face a parallel consideration. Accelerated review timelines compress the window between Phase III lock and commercial-scale process validation, requiring that process performance qualification batches are initiated well ahead of a potential approval date. For a novel KRAS inhibitor entering a market with an established comparator, launch readiness and GMP compliance at commercial scale will be evaluated in close sequence.

The Phase III mortality data will form the evidentiary core of any regulatory submission, and the completeness of the CMC package assembled in parallel will determine how cleanly Roche can convert a strong clinical signal into an approved product.

Source: Media4Growth via Indian Pharma Post, 26 October 2026.